<VariationArchive VariationID="371705" VariationName="NM_000098.3(CPT2):c.1774_1775del (p.Leu592fs)" VariationType="Deletion" Accession="VCV000371705" Version="3" RecordType="classified" NumberOfSubmissions="4" NumberOfSubmitters="2" DateLastUpdated="2024-02-28" DateCreated="2017-01-07" MostRecentSubmission="2024-02-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="357127" VariationID="371705">
      <GeneList>
        <Gene Symbol="CPT2" FullName="carnitine palmitoyltransferase 2" GeneID="1376" HGNC_ID="HGNC:2330" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>1p32.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="53196824" stop="53214197" display_start="53196824" display_stop="53214197" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="53662100" stop="53679868" display_start="53662100" display_stop="53679868" Strand="+" />
          </Location>
          <OMIM>600650</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000098.3(CPT2):c.1774_1775del (p.Leu592fs)</Name>
      <CanonicalSPDI>NC_000001.11:53213391:CT:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>1p32.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="53213392" stop="53213393" display_start="53213392" display_stop="53213393" variantLength="2" positionVCF="53213391" referenceAlleleVCF="ACT" alternateAlleleVCF="A" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="53679064" stop="53679065" display_start="53679064" display_stop="53679065" variantLength="2" positionVCF="53679063" referenceAlleleVCF="ACT" alternateAlleleVCF="A" />
      </Location>
      <ProteinChange>L592fs</ProteinChange>
      <ProteinChange>L569fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000001.10" sequenceAccession="NC_000001" sequenceVersion="10" change="g.53679064_53679065del" Assembly="GRCh37">
            <Expression>NC_000001.10:g.53679064_53679065del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000001.11" sequenceAccession="NC_000001" sequenceVersion="11" change="g.53213392_53213393del" Assembly="GRCh38">
            <Expression>NC_000001.11:g.53213392_53213393del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008035.1" sequenceAccession="NG_008035" sequenceVersion="1" change="g.21964_21965del">
            <Expression>NG_008035.1:g.21964_21965del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000098.3" sequenceAccession="NM_000098" sequenceVersion="3" change="c.1774_1775del" MANESelect="true">
            <Expression>NM_000098.3:c.1774_1775del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000089.1" sequenceAccession="NP_000089" sequenceVersion="1" change="p.Leu592fs">
            <Expression>NP_000089.1:p.Leu592fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001330589.2" sequenceAccession="NM_001330589" sequenceVersion="2" change="c.1705_1706del">
            <Expression>NM_001330589.2:c.1705_1706del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001317518.1" sequenceAccession="NP_001317518" sequenceVersion="1" change="p.Leu569fs">
            <Expression>NP_001317518.1:p.Leu569fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA859274" DB="ClinGen" />
        <XRef Type="rs" ID="767004984" DB="dbSNP" />
      </XRefList>
      <AlleleFrequencyList>
        <AlleleFrequency Value="0.00000" Source="The Genome Aggregation Database (gnomAD), exomes" />
        <AlleleFrequency Value="0.00001" Source="Exome Aggregation Consortium (ExAC)" />
        <AlleleFrequency Value="0.00001" Source="The Genome Aggregation Database (gnomAD)" />
        <AlleleFrequency Value="0.00001" Source="Trans-Omics for Precision Medicine (TOPMed)" />
      </AlleleFrequencyList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000098.3(CPT2):c.1774_1775del (p.Leu592fs) AND Carnitine palmitoyl transferase II deficiency, myopathic form" Accession="RCV000409282" Version="2">
        <ClassifiedConditionList TraitSetID="2468">
          <ClassifiedCondition DB="MedGen" ID="C1833508">Carnitine palmitoyl transferase II deficiency, myopathic form</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2016-02-12" SubmissionCount="1">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000098.3(CPT2):c.1774_1775del (p.Leu592fs) AND Carnitine palmitoyl transferase II deficiency, severe infantile form" Accession="RCV000410414" Version="2">
        <ClassifiedConditionList TraitSetID="2467">
          <ClassifiedCondition DB="MedGen" ID="C1833511">Carnitine palmitoyl transferase II deficiency, severe infantile form</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2016-02-12" SubmissionCount="1">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000098.3(CPT2):c.1774_1775del (p.Leu592fs) AND Carnitine palmitoyl transferase II deficiency, neonatal form" Accession="RCV000411459" Version="2">
        <ClassifiedConditionList TraitSetID="2470">
          <ClassifiedCondition DB="MedGen" ID="C1833518">Carnitine palmitoyl transferase II deficiency, neonatal form</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2016-02-12" SubmissionCount="1">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000098.3(CPT2):c.1774_1775del (p.Leu592fs) AND Carnitine palmitoyltransferase II deficiency" Accession="RCV003741177" Version="1">
        <ClassifiedConditionList TraitSetID="10067">
          <ClassifiedCondition DB="MedGen" ID="C0342790">Carnitine palmitoyltransferase II deficiency</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-09-08" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-09-08" NumberOfSubmissions="4" NumberOfSubmitters="2" DateCreated="2017-01-07" MostRecentSubmission="2024-02-20">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic/Likely pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">17936304</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21913903</ID>
        </Citation>
        <DescriptionHistory Dated="2024-02-17">
          <Description>Likely pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="10067" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="6221" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Carnitine palmitoyl transferase 2 deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Carnitine palmitoyltransferase II deficiency</ElementValue>
                <XRef ID="MONDO:0015515" DB="MONDO" />
                <XRef ID="238002005" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Carnitine palmitoyltransferase deficiency type 2</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">CPT2</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="1121" />
                <XRef ID="1121" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Carnitine palmitoyltransferase II (CPT II) deficiency is a disorder of long-chain fatty-acid oxidation. The three clinical presentations are lethal neonatal form, severe infantile hepatocardiomuscular form, and myopathic form (which is usually mild and can manifest from infancy to adulthood). While the former two are severe multisystemic diseases characterized by liver failure with hypoketotic hypoglycemia, cardiomyopathy, seizures, and early death, the latter is characterized by exercise-induced muscle pain and weakness, sometimes associated with myoglobinuria. The myopathic form of CPT II deficiency is the most common disorder of lipid metabolism affecting skeletal muscle and the most frequent cause of hereditary myoglobinuria. Males are more likely to be affected than females.</Attribute>
                <XRef ID="NBK1253" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301431</ID>
                <ID Source="BookShelf">NBK1253</ID>
              </Citation>
              <Citation Type="general" Abbrev="ESC, 2014">
                <ID Source="PubMed">25173338</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Carnitine-Palmitoyltransferase-2-Deficiency-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Increased C16 and/or C18:1 Acylcarnitine, Carnitine Palmitoyltransferase II (CPT II) Deficiency and Carnitine Acylcarnitine Translocase (CACT) Deficiency, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/C16-C18-Elevated-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, C16 +/- C18:1 Elevated: CPT II or CACT, 2022</CitationText>
              </Citation>
              <XRef ID="157" DB="Orphanet" />
              <XRef ID="C0342790" DB="MedGen" />
              <XRef ID="MONDO:0015515" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="2467" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="686" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Carnitine palmitoyltransferase II deficiency, infantile</ElementValue>
                <XRef ID="Carnitine+palmitoyltransferase+II+deficiency%2C+infantile/7904" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY WITH HYPOKETOTIC HYPOGLYCEMIA</ElementValue>
                <XRef Type="MIM" ID="600649" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, HEPATOCARDIOMUSCULAR</ElementValue>
                <XRef Type="MIM" ID="600649" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CPT II DEFICIENCY, HEPATIC</ElementValue>
                <XRef Type="MIM" ID="600649" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CPT2 DEFICIENCY, INFANTILE</ElementValue>
                <XRef Type="MIM" ID="600649" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CPT II deficiency, infantile</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Carnitine palmitoyl transferase II deficiency, severe infantile form</ElementValue>
                <XRef ID="MONDO:0010914" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">Carnitine palmitoyltransferase II (CPT II) deficiency is a disorder of long-chain fatty-acid oxidation. The three clinical presentations are lethal neonatal form, severe infantile hepatocardiomuscular form, and myopathic form (which is usually mild and can manifest from infancy to adulthood). While the former two are severe multisystemic diseases characterized by liver failure with hypoketotic hypoglycemia, cardiomyopathy, seizures, and early death, the latter is characterized by exercise-induced muscle pain and weakness, sometimes associated with myoglobinuria. The myopathic form of CPT II deficiency is the most common disorder of lipid metabolism affecting skeletal muscle and the most frequent cause of hereditary myoglobinuria. Males are more likely to be affected than females.</Attribute>
                <XRef ID="NBK1253" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17150" />
                <XRef ID="17150" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301431</ID>
                <ID Source="BookShelf">NBK1253</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Carnitine-Palmitoyltransferase-2-Deficiency-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Increased C16 and/or C18:1 Acylcarnitine, Carnitine Palmitoyltransferase II (CPT II) Deficiency and Carnitine Acylcarnitine Translocase (CACT) Deficiency, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/C16-C18-Elevated-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, C16 +/- C18:1 Elevated: CPT II or CACT, 2022</CitationText>
              </Citation>
              <XRef ID="228305" DB="Orphanet" />
              <XRef ID="C1833511" DB="MedGen" />
              <XRef ID="MONDO:0010914" DB="MONDO" />
              <XRef Type="MIM" ID="600649" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="2468" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="727" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, ADULT-ONSET</ElementValue>
                <XRef Type="MIM" ID="255110" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, MYOPATHIC</ElementValue>
                <XRef Type="MIM" ID="255110" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Carnitine palmitoyltransferase II deficiency, myopathic, stress-induced</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">CPT II DEFICIENCY, MYOPATHIC</ElementValue>
                <XRef Type="MIM" ID="255110" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CPT2 DEFICIENCY, LATE-ONSET</ElementValue>
                <XRef Type="MIM" ID="255110" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CPT II deficiency, myopathic, stress-induced</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Carnitine palmitoyltransferase II deficiency, late-onset</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Carnitine palmitoyl transferase II deficiency, myopathic form</ElementValue>
                <XRef ID="MONDO:0009704" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">Carnitine palmitoyltransferase II (CPT II) deficiency is a disorder of long-chain fatty-acid oxidation. The three clinical presentations are lethal neonatal form, severe infantile hepatocardiomuscular form, and myopathic form (which is usually mild and can manifest from infancy to adulthood). While the former two are severe multisystemic diseases characterized by liver failure with hypoketotic hypoglycemia, cardiomyopathy, seizures, and early death, the latter is characterized by exercise-induced muscle pain and weakness, sometimes associated with myoglobinuria. The myopathic form of CPT II deficiency is the most common disorder of lipid metabolism affecting skeletal muscle and the most frequent cause of hereditary myoglobinuria. Males are more likely to be affected than females.</Attribute>
                <XRef ID="NBK1253" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17149" />
                <XRef ID="17149" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301431</ID>
                <ID Source="BookShelf">NBK1253</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Carnitine-Palmitoyltransferase-2-Deficiency-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Increased C16 and/or C18:1 Acylcarnitine, Carnitine Palmitoyltransferase II (CPT II) Deficiency and Carnitine Acylcarnitine Translocase (CACT) Deficiency, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/C16-C18-Elevated-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, C16 +/- C18:1 Elevated: CPT II or CACT, 2022</CitationText>
              </Citation>
              <XRef ID="157" DB="Orphanet" />
              <XRef ID="228302" DB="Orphanet" />
              <XRef ID="C1833508" DB="MedGen" />
              <XRef ID="MONDO:0009704" DB="MONDO" />
              <XRef Type="MIM" ID="255110" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="2470" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="4739" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, ANTENATAL</ElementValue>
                <XRef Type="MIM" ID="608836" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, NEONATAL</ElementValue>
                <XRef Type="MIM" ID="608836" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CPT II DEFICIENCY, LETHAL NEONATAL</ElementValue>
                <XRef Type="MIM" ID="608836" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CPT2 DEFICIENCY, LETHAL NEONATAL</ElementValue>
                <XRef Type="MIM" ID="608836" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Carnitine palmitoyl transferase II deficiency, neonatal form</ElementValue>
                <XRef ID="MONDO:0012136" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Carnitine palmitoyltransferase II deficiency, lethal neonatal</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">Carnitine palmitoyltransferase II (CPT II) deficiency is a disorder of long-chain fatty-acid oxidation. The three clinical presentations are lethal neonatal form, severe infantile hepatocardiomuscular form, and myopathic form (which is usually mild and can manifest from infancy to adulthood). While the former two are severe multisystemic diseases characterized by liver failure with hypoketotic hypoglycemia, cardiomyopathy, seizures, and early death, the latter is characterized by exercise-induced muscle pain and weakness, sometimes associated with myoglobinuria. The myopathic form of CPT II deficiency is the most common disorder of lipid metabolism affecting skeletal muscle and the most frequent cause of hereditary myoglobinuria. Males are more likely to be affected than females.</Attribute>
                <XRef ID="NBK1253" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17151" />
                <XRef ID="17151" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301431</ID>
                <ID Source="BookShelf">NBK1253</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Carnitine-Palmitoyltransferase-2-Deficiency-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Increased C16 and/or C18:1 Acylcarnitine, Carnitine Palmitoyltransferase II (CPT II) Deficiency and Carnitine Acylcarnitine Translocase (CACT) Deficiency, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/C16-C18-Elevated-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, C16 +/- C18:1 Elevated: CPT II or CACT, 2022</CitationText>
              </Citation>
              <XRef ID="228308" DB="Orphanet" />
              <XRef ID="C1833518" DB="MedGen" />
              <XRef ID="MONDO:0012136" DB="MONDO" />
              <XRef Type="MIM" ID="608836" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="951256" SubmissionDate="2016-11-23" DateLastUpdated="2022-12-24" DateCreated="2017-01-07">
        <ClinVarSubmissionID localKey="836764|OMIM:255110" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000487506" DateUpdated="2022-12-24" DateCreated="2017-01-07" Type="SCV" Version="2" SubmitterName="Counsyl" OrgID="320494" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2016-02-12">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Counsyl Autosomal and X-linked Recessive Disease Classification criteria (2015)</Attribute>
          <Citation Type="general">
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rb7nm21v/ar_xl2015criteria.pdf</URL>
            <CitationText>mdi-5618_320494_Counsyl Autosomal and X-linked Recessive Disease Classification criteria (2015).pdf</CitationText>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CPT2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000098.2:c.1774_1775delCT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="255110" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>Counsyl2016</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="951257" SubmissionDate="2016-11-23" DateLastUpdated="2022-12-24" DateCreated="2017-01-07">
        <ClinVarSubmissionID localKey="836764|OMIM:600649" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000487507" DateUpdated="2022-12-24" DateCreated="2017-01-07" Type="SCV" Version="2" SubmitterName="Counsyl" OrgID="320494" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2016-02-12">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Counsyl Autosomal and X-linked Recessive Disease Classification criteria (2015)</Attribute>
          <Citation Type="general">
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rb7nm21v/ar_xl2015criteria.pdf</URL>
            <CitationText>mdi-5618_320494_Counsyl Autosomal and X-linked Recessive Disease Classification criteria (2015).pdf</CitationText>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CPT2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000098.2:c.1774_1775delCT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="600649" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>Counsyl2016</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="951258" SubmissionDate="2016-11-23" DateLastUpdated="2022-12-24" DateCreated="2017-01-07">
        <ClinVarSubmissionID localKey="836764|OMIM:608836" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000487508" DateUpdated="2022-12-24" DateCreated="2017-01-07" Type="SCV" Version="2" SubmitterName="Counsyl" OrgID="320494" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2016-02-12">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Counsyl Autosomal and X-linked Recessive Disease Classification criteria (2015)</Attribute>
          <Citation Type="general">
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rb7nm21v/ar_xl2015criteria.pdf</URL>
            <CitationText>mdi-5618_320494_Counsyl Autosomal and X-linked Recessive Disease Classification criteria (2015).pdf</CitationText>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CPT2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000098.2:c.1774_1775delCT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="608836" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>Counsyl2016</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="8349562" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2024-02-20">
        <ClinVarSubmissionID localKey="6811911|MedGen:C0342790" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004561693" DateUpdated="2024-02-20" DateCreated="2024-02-20" Type="SCV" Version="1" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-09-08">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">17936304</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21913903</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Leu592Glufs*16) in the CPT2 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 67 amino acid(s) of the CPT2 protein. This variant is present in population databases (rs767004984, gnomAD 0.007%). This variant has not been reported in the literature in individuals affected with CPT2-related conditions. ClinVar contains an entry for this variant (Variation ID: 371705). This variant disrupts a region of the CPT2 protein in which other variant(s) (p.Glu645Argfs*5) have been determined to be pathogenic (PMID: 17936304, 21913903). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CPT2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000001.10:g.53679064_53679065del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0342790" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14200314</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="8349562" TraitType="Disease" MappingType="XRef" MappingValue="C0342790" MappingRef="MedGen">
        <MedGen CUI="C0342790" Name="Carnitine palmitoyltransferase II deficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="951256" TraitType="Disease" MappingType="XRef" MappingValue="255110" MappingRef="OMIM">
        <MedGen CUI="C1833508" Name="Carnitine palmitoyl transferase II deficiency, myopathic form" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="951257" TraitType="Disease" MappingType="XRef" MappingValue="600649" MappingRef="OMIM">
        <MedGen CUI="C1833511" Name="Carnitine palmitoyl transferase II deficiency, severe infantile form" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="951258" TraitType="Disease" MappingType="XRef" MappingValue="608836" MappingRef="OMIM">
        <MedGen CUI="C1833518" Name="Carnitine palmitoyl transferase II deficiency, neonatal form" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

